

Nicholas James

List of Publications by Citations

Source: <https://exaly.com/author-pdf/5896203/nicholas-james-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

75
papers

9,373
citations

28
h-index

87
g-index

87
ext. papers

11,567
ext. citations

9.7
avg, IF

5.11
L-index

#	Paper	IF	Citations
75	Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. <i>New England Journal of Medicine</i> , 2004 , 351, 1502-12	59.2	4314
74	Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. <i>Lancet, The</i> , 2016 , 387, 1163-77	40	1115
73	Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy. <i>New England Journal of Medicine</i> , 2017 , 377, 338-351	59.2	898
72	Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. <i>Lancet, The</i> , 2018 , 392, 2353-2366	40	510
71	Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial. <i>Lancet Oncology, The</i> , 2014 , 15, 738-46	21.7	357
70	Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data. <i>Lancet Oncology, The</i> , 2016 , 17, 243-256	21.7	268
69	Homocysteine-induced inhibition of endothelium-dependent relaxation in rabbit aorta: role for superoxide anions. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2000 , 20, 422-7	9.4	171
68	Speeding up the evaluation of new agents in cancer. <i>Journal of the National Cancer Institute</i> , 2008 , 100, 1204-14	9.7	109
67	Failure-Free Survival and Radiotherapy in Patients With Newly Diagnosed Nonmetastatic Prostate Cancer: Data From Patients in the Control Arm of the STAMPEDE Trial. <i>JAMA Oncology</i> , 2016 , 2, 348-57	13.4	108
66	Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: A systematic review and meta-analysis. <i>European Journal of Cancer</i> , 2017 , 84, 88-101	7.5	100
65	Issues in applying multi-arm multi-stage methodology to a clinical trial in prostate cancer: the MRC STAMPEDE trial. <i>Trials</i> , 2009 , 10, 39	2.8	95
64	Flexible trial design in practice - stopping arms for lack-of-benefit and adding research arms mid-trial in STAMPEDE: a multi-arm multi-stage randomized controlled trial. <i>Trials</i> , 2012 , 13, 168	2.8	94
63	Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial. <i>Lancet, The</i> , 2020 , 396, 1413-1421	40	92
62	Genomic complexity of urothelial bladder cancer revealed in urinary cfDNA. <i>European Journal of Human Genetics</i> , 2016 , 24, 1167-74	5.3	85
61	Abiraterone in "High-" and "Low-risk" Metastatic Hormone-sensitive Prostate Cancer. <i>European Urology</i> , 2019 , 76, 719-728	10.2	75
60	Primary Results from SAUL, a Multinational Single-arm Safety Study of Atezolizumab Therapy for Locally Advanced or Metastatic Urothelial or Nonurothelial Carcinoma of the Urinary Tract. <i>European Urology</i> , 2019 , 76, 73-81	10.2	74
59	Systemic therapy for advancing or metastatic prostate cancer (STAMPEDE): a multi-arm, multistage randomized controlled trial. <i>BJU International</i> , 2009 , 103, 464-9	5.6	58

58	UroMark-a urinary biomarker assay for the detection of bladder cancer. <i>Clinical Epigenetics</i> , 2017 , 9, 8	7.7	55
57	Multiplex PCR and Next Generation Sequencing for the Non-Invasive Detection of Bladder Cancer. <i>PLoS ONE</i> , 2016 , 11, e0149756	3.7	52
56	The West Midlands Bladder Cancer Prognosis Programme: rationale and design. <i>BJU International</i> , 2010 , 105, 784-8	5.6	43
55	Testing many treatments within a single protocol over 10 years at MRC Clinical Trials Unit at UCL: Multi-arm, multi-stage platform, umbrella and basket protocols. <i>Clinical Trials</i> , 2017 , 14, 451-461	2.2	38
54	Adding Celecoxib With or Without Zoledronic Acid for Hormone-Naïve Prostate Cancer: Long-Term Survival Results From an Adaptive, Multiarm, Multistage, Platform, Randomized Controlled Trial. <i>Journal of Clinical Oncology</i> , 2017 , 35, 1530-1541	2.2	37
53	Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial. <i>Lancet Oncology, The</i> , 2020 , 21, 105-120	21.7	35
52	This is a platform alteration: a trial management perspective on the operational aspects of adaptive and platform and umbrella protocols. <i>Trials</i> , 2019 , 20, 264	2.8	31
51	Toward Personalised Liquid Biopsies for Urothelial Carcinoma: Characterisation of ddPCR and Urinary cfDNA for the Detection of the 228 G>A/T Mutation. <i>Bladder Cancer</i> , 2018 , 4, 41-48	1	31
50	Changing platforms without stopping the train: experiences of data management and data management systems when adapting platform protocols by adding and closing comparisons. <i>Trials</i> , 2019 , 20, 294	2.8	29
49	Safe Use of Immune Checkpoint Inhibitors in the Multidisciplinary Management of Urological Cancer: The European Association of Urology Position in 2019. <i>European Urology</i> , 2019 , 76, 368-380	10.2	26
48	Patient-reported Quality of Life Outcomes in Patients Treated for Muscle-invasive Bladder Cancer with Radiotherapy ± Chemotherapy in the BC2001 Phase III Randomised Controlled Trial. <i>European Urology</i> , 2020 , 77, 260-268	10.2	26
47	Targeted deep sequencing of urothelial bladder cancers and associated urinary DNA: a 23-gene panel with utility for non-invasive diagnosis and risk stratification. <i>BJU International</i> , 2019 , 124, 532-544	5.6	23
46	Shifting paradigms in the estimation of survival for castration-resistant prostate cancer: A tertiary academic center experience. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015 , 33, 338.e1-7	2.8	23
45	Survey of the Impact of COVID-19 on Oncologists' Decision Making in Cancer. <i>JCO Global Oncology</i> , 2020 , 6, 1248-1257	3.7	22
44	A comparison of patient and tumour characteristics in two UK bladder cancer cohorts separated by 20 years. <i>BJU International</i> , 2013 , 112, 169-75	5.6	20
43	Hypofractionated radiotherapy in locally advanced bladder cancer: an individual patient data meta-analysis of the BC2001 and BCON trials. <i>Lancet Oncology, The</i> , 2021 , 22, 246-255	21.7	20
42	Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol. <i>Lancet, The</i> , 2021 ,	4.0	18
41	Biology of testicular germ cell tumors. <i>Expert Review of Anticancer Therapy</i> , 2008 , 8, 1659-73	3.5	15

40	Addition of Docetaxel to First-line Long-term Hormone Therapy in Prostate Cancer (STAMPEDE): Modelling to Estimate Long-term Survival, Quality-adjusted Survival, and Cost-effectiveness. <i>European Urology Oncology</i> , 2018 , 1, 449-458	6.7	15
39	Defining bowel dose volume constraints for bladder radiotherapy treatment planning. <i>Clinical Oncology</i> , 2015 , 27, 22-9	2.8	14
38	Transdermal oestradiol as a method of androgen suppression for prostate cancer within the STAMPEDE trial platform. <i>BJU International</i> , 2018 , 121, 680-683	5.6	14
37	Defining the frequency of human papillomavirus and polyomavirus infection in urothelial bladder tumours. <i>Scientific Reports</i> , 2018 , 8, 11290	4.9	13
36	BC2001 long-term outcomes: A phase III randomized trial of chemoradiotherapy versus radiotherapy (RT) alone and standard RT versus reduced high-dose volume RT in muscle-invasive bladder cancer.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 280-280	2.2	13
35	A Systematic Review of the Role of Definitive Local Treatment in Patients with Clinically Lymph Node-positive Prostate Cancer. <i>European Urology Oncology</i> , 2019 , 2, 294-301	6.7	13
34	Exploring the roles of urinary HAI-1, EpCAM & EGFR in bladder cancer prognosis & risk stratification. <i>Oncotarget</i> , 2018 , 9, 25244-25253	3.3	10
33	Association of Bone Metastatic Burden With Survival Benefit From Prostate Radiotherapy in Patients With Newly Diagnosed Metastatic Prostate Cancer: A Secondary Analysis of a Randomized Clinical Trial. <i>JAMA Oncology</i> , 2021 , 7, 555-563	13.4	10
32	Outcomes in Patients with Muscle-invasive Bladder Cancer Treated with Neoadjuvant Chemotherapy Followed by (Chemo)radiotherapy in the BC2001 Trial. <i>European Urology</i> , 2021 , 79, 307-315	10.2	9
31	A Comparative Analysis of the Influence of Gender, Pathway Delays, and Risk Factor Exposures on the Long-term Outcomes of Bladder Cancer. <i>European Urology Focus</i> , 2015 , 1, 82-89	5.1	8
30	Predictive factors for response to abiraterone in metastatic castration refractory prostate cancer. <i>Anticancer Research</i> , 2015 , 35, 1057-63	2.3	8
29	Health-related quality of life around the time of diagnosis in patients with bladder cancer. <i>BJU International</i> , 2019 , 124, 984-991	5.6	7
28	Flexible trial design in practice Dropping and adding arms in STAMPEDE: a multi-arm multi-stage randomised controlled trial. <i>Trials</i> , 2011 , 12,	2.8	7
27	Endocrine therapy and other targeted therapies for metastatic breast cancer. <i>Expert Review of Anticancer Therapy</i> , 2004 , 4, 1179-95	3.5	7
26	Non-Coding Mutations in Urothelial Bladder Cancer: Biological and Clinical Relevance and Potential Utility as Biomarkers. <i>Bladder Cancer</i> , 2019 , 5, 263-272	1	7
25	A Practical Application of Value of Information and Prospective Payback of Research to Prioritize Evaluative Research. <i>Medical Decision Making</i> , 2016 , 36, 321-34	2.5	6
24	Integrated Care in Prostate Cancer (ICARE-P): Nonrandomized Controlled Feasibility Study of Online Holistic Needs Assessment, Linking the Patient and the Health Care Team. <i>JMIR Research Protocols</i> , 2017 , 6, e147	2	6
23	STAMPEDE trial and patients with non-metastatic prostate cancer - AuthorsReply. <i>Lancet, The</i> , 2016 , 388, 235-6	40	6

22	Oligometastatic Prostate Cancer Should Be Studied and Treated Differently to High-volume Disease. Con: The Underlying Biology is the Same, So They Should Not Be Treated Differently. <i>European Urology Focus</i> , 2019 , 5, 119-122	5.1	5
21	Back-Splicing Transcript Isoforms (Circular RNAs) Affect Biologically Relevant Pathways and Offer an Additional Layer of Information to Stratify NMIBC Patients. <i>Frontiers in Oncology</i> , 2020 , 10, 812	5.3	5
20	The Automated Bone Scan Index as a Predictor of Response to Prostate Radiotherapy in Men with Newly Diagnosed Metastatic Prostate Cancer: An Exploratory Analysis of STAMPEDE® "M1 RT Comparison". <i>European Urology Oncology</i> , 2020 , 3, 412-419	6.7	5
19	CD40L membrane retention enhances the immunostimulatory effects of CD40 ligation. <i>Scientific Reports</i> , 2020 , 10, 342	4.9	5
18	Temsirolimus for patients with metastatic renal cell carcinoma: outcomes in patients receiving temsirolimus within a compassionate use program in a tertiary referral center. <i>Drug Design, Development and Therapy</i> , 2015 , 9, 13-9	4.4	4
17	Celecoxib with or without zoledronic acid for hormone-naïve prostate cancer: Survival results from STAMPEDE (NCT00268476).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 162-162	2.2	4
16	Adding abiraterone for men with high-risk prostate cancer (PCa) starting long-term androgen deprivation therapy (ADT): Survival results from STAMPEDE (NCT00268476).. <i>Journal of Clinical Oncology</i> , 2017 , 35, LBA5003-LBA5003	2.2	4
15	Addition of docetaxel to first-line long-term hormone therapy in prostate cancer (STAMPEDE): Long-term survival, quality-adjusted survival, and cost-effectiveness analysis.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 162-162	2.2	4
14	Targeting IGF-1/2 with xentuzumab (Xe) plus enzalutamide (En) in metastatic castration-resistant prostate cancer (mCRPC) after progression on docetaxel chemotherapy (DCt) and abiraterone (Abi): Randomized phase II trial results.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 5030-5030	2.2	4
13	Quality of Life in Men With Prostate Cancer Randomly Allocated to Receive Docetaxel or Abiraterone in the STAMPEDE Trial. <i>Journal of Clinical Oncology</i> , 2021 , JCO2100728	2.2	3
12	Adding abiraterone for men with high-risk prostate cancer (PCa) starting long-term androgen deprivation therapy (ADT): Survival results from STAMPEDE (NCT00268476).. <i>Journal of Clinical Oncology</i> , 2017 , 35, LBA5003-LBA5003	2.2	2
11	Outcome of BC2001 patients (CRUK/01/004) who received neoadjuvant chemotherapy prior to randomization to chemo-radiotherapy (cRT) versus radiotherapy (RT).. <i>Journal of Clinical Oncology</i> , 2017 , 35, 298-298	2.2	2
10	Diagnosis and Treatment of Prostate Cancer: What Americans Can Learn From International Oncologists. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017 , 37, 344-357	7.1	1
9	Quality of life (QL) of patients (pts) treated for muscle invasive bladder cancer (MIBC) with radiotherapy (RT) +/- chemotherapy (CT) in the BC2001 trial (CRUK/01/004): Analysis of impact of treatment at an individual level.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 292-292	2.2	1
8	Phase II open-label study of S-588410 as maintenance monotherapy after first-line platinum-containing chemotherapy in patients with advanced or metastatic urothelial carcinoma.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 440-440	2.2	1
7	Predictive biomarkers for survival benefit with ramucirumab in urothelial cancer in the RANGE trial.. <i>Nature Communications</i> , 2022 , 13, 1878	17.4	1
6	Cost-utility analysis of adding abiraterone acetate plus prednisone/prednisolone to long-term hormone therapy in newly diagnosed advanced prostate cancer in England: Lifetime decision model based on STAMPEDE trial data. <i>PLoS ONE</i> , 2022 , 17, e0269192	3.7	1
5	Reply to Wei Liu, Xiaoping Liu, Sheng Li@ Letter to the Editor, re: Robert A. Huddart, Emma Hall, Rebecca Lewis, et al. Patient-reported Quality of Life Outcomes in Patients Treated for Muscle-invasive Bladder Cancer with Radiotherapy ± Chemotherapy in the BC2001 Phase III Randomised Controlled Trial. <i>European Urology</i> , 2020 , 77, e156-e157	10.2	

- 4 Reply to Che-Kai Tsao, Matthew D. Galsky, and William K. Oh [©] Platinum Opinion. Docetaxel for Metastatic Hormone-Sensitive Prostate Cancer: Urgent Need To Minimize The Risk Of Neutropenic Fever. *Eur Urol* 2016;70:707-708. *European Urology*, **2017**, 72, e17 10.2
- 3 Reply to Santhanam Sundar and Paul Symonds Letter to the Editor re: Syed A. Hussain, Nuria Porta, Emma Hall, et al. Outcomes in Patients with Muscle-invasive Bladder Cancer Treated with Neoadjuvant Chemotherapy Followed by (Chemo)radiotherapy in the BC2001 Trial. *Eur Urol* 2021;79:307-15. *European Urology*, **2021**, 80, e51-e52 10.2
- 2 Real-world evidence from a single U.K. cancer center for atezolizumab in second-line setting in advanced urothelial cancer: Moving beyond clinical trials.. *Journal of Clinical Oncology*, **2022**, 40, 461-461^{2.2}
- 1 Case of the month from the University of Sheffield, UK : Expediting definitive treatment in patients with invasive bladder cancer: an MRI -guided pathway. *BJU International*, **2022**, 129, 691-694 5.6